Legal Disclaimer
This page provides general legal orientation for Netherlands, not legal advice. Regulations change frequently. Always verify current rules with MEB and consult a qualified professional.
Peptide Legal Status in Netherlands
The Netherlands regulates medicines through the MEB/CBG under the Geneesmiddelenwet (Medicines Act). GLP-1 agonists are EMA-authorized and available by prescription. The IGJ (Health and Youth Care Inspectorate) enforces medicines regulation. The Netherlands has a pragmatic regulatory approach — compounding is permitted, and online prescribing is allowed within established frameworks.
Regulator
MEB (Medicines Evaluation Board) / CBG (College ter Beoordeling van Geneesmiddelen) — Official website
Key Facts
Compounding Pharmacy Rules
Telehealth Prescribing
Peptide Categories in Netherlands
Approved
Semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro), liraglutide (Saxenda) — EMA-authorized, available by prescription. Reimbursement through zorgverzekering is limited for weight loss; most are self-pay.
Research / Unapproved
BPC-157, TB-500, GHRPs — no marketing authorization. Sale as research chemicals for human use is prohibited under the Geneesmiddelenwet. IGJ may take enforcement action.
Banned / Restricted
Unauthorized medicines. Check current IGJ enforcement priorities and opioid/controlled substance scheduling.
Key Legislation
- Geneesmiddelenwet (Medicines Act)
- Wet op de beroepen in de individuele gezondheidszorg (BIG Act)
- Wet geneeskundige behandelingsovereenkomst (WGBO)
Peptides in Netherlands: FAQ
Sources
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.
Peptide Laws in Other Countries
Get Netherlands regulatory updates
Stay informed when country-specific legal pages, routing guidance, and safety guidance change.
No spam. Unsubscribe anytime.